Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.
Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol. 2025 Oct; 9:e2500538.